Comparative pharmacodynamic time-course of bemiparin and enoxaparin in healthy volunteers

International Journal of Clinical Pharmacology and Therapeutics

Volumn 47, Issue 12, 2009, Pages 726-732

  Antonijoan, R M ^a,b   Rico, S ^a,b   Martinez Gonzalez J ^c   Borrell, M ^a   Valcarcel, D ^a   Fontcuberta, J ^a   Barbanoj, M J ^a,b  

^a HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^b UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^c AUTONOMOUS UNIVERSITY OF MADRID   (Spain)

Author keywords

Bemiparin; Enoxaparin; Low molecular; Pharmaco dynamics; Time course; Weight heparin

Indexed keywords

BEMIPARIN; ENOXAPARIN; TISSUE FACTOR PATHWAY INHIBITOR;

ADULT; AREA UNDER THE CURVE; ARTICLE; BIOCHEMISTRY; BLOOD EXAMINATION; BLOOD SAMPLING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DEPOLYMERIZATION; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; ELECTROCARDIOGRAM; HEPARIN INDUCED THROMBOCYTOPENIA; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; PARTIAL THROMBOPLASTIN TIME; PROTHROMBIN TIME; PULSE RATE; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SINGLE BLIND PROCEDURE; SINGLE DRUG DOSE; SYSTOLIC BLOOD PRESSURE; THROMBOPLASTIN TIME; TIME TO MAXIMUM PLASMA CONCENTRATION; URINALYSIS;

EID: 71849116146     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: 10.5414/CPP47726     Document Type: Article

References (24)

1. Ansell J. Factor Xa or thrombin: is factor Xa a better target?. J Thromb Haemost. 2007; 5(Suppl): 60-64.
2. Barrett JS, Gibiansky E, Hull RD, Planés A, Pentikis H, Hainer JW, Hua TA, Gastonguay M. Population pharmacodynamics in patients receiving tinzaparin for the prevention and treatment of deep vein thrombosis. Int J Clin Pharmacol Ther. 2001; 39: 431-46.
3. Borrell M, Llobet D, Ortin R, Felices R, Vallv, C, Mateo J, Souto J, Fontcuberta J. Thromboplastin-thrombomodulin-mediated time: a new global test sensitive to protein S deficiency and increased levels of factors II, V, VII and X. Haematologica. 2002; 87: 415-419.
4. Broze GJ Jr. The rediscovery and isolation of TFPI. J Thromb Haemost. 2003; 1: 1671-1675.
5. Christidou FN, Frangia TK, Bamichas GI, Gionanlis LC, Natse TA, Georgoulis IE, Sombolos KI. Comparison of two low-molecular weight heparins (LMWHs), tinzaparin and bemiparin, during hemodialysis. Int J Clin Pharmacol Ther. 2005; 43: 335-338.
6. Collignon F, Frydman A, Caplain H, Ozoux ML, Le Roux Y, Bouthier J, Thébault JJ. Comparison of the pharmacokinetic profiles of three low molecular mass heparins - dalteparin, enoxaparin and nadroparin - administered subcutaneously in healthy volunteers (doses for prevention of thromboembolism). Thromb Haemost. 1995; 73: 630-640.
7. Cornelli U, Fareed J. Human pharmacokinetics of low molecular weight heparins. Semin Thromb Hemost. 1999; 25(Suppl.): 57-61.
8. Depasse F, Gonzalez de Suso MJ, Lagoutte I, Fontcuberta J, Borrell M, Samama MM. Comparative study of the pharmacokinetic profiles of two LMWHs - bemiparin (3500 IU, anti-Xa) and tinzaparin (4500 IU, anti-Xa) - administered subcutaneously to healthy male volunteers. Thromb Res. 2003; 109: 109-117.
9. Falkon L, Bayes M, Frontera G, Gari M, Barbanoj M, Fontcuberta J. Pharmacokinetics and tolerability of a new low molecular mass heparin (RO-11) in healthy volunteers - a dose-finding study within the therapeutical range. Thromb Haemost. 1997; 77: 133-136.
10. Falkon L, Saenz-Campos D, Antonijoan R, Martin S, Barbanoj M, Fontcuberta J. Bioavailability and pharmacokinetics of a new low molecular weight heparin (RO-11) - a three way cross-over study in healthy volunteers. Thromb Res. 1995; 78: 77-86.
11. Fareed J, Walenga JM. Why differentiate low molecular weight heparins for venous thromboembolism?. Thromb J. 2007; 5: 8.
12. Fragmin® package insert. Pharmacia & Upjohn Co., Kalamazoo, MI, USA. March 2004.
13. Hirsh J, Raschke R. Heparin and low-molecular-weight heparin: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004; 126(Suppl): 188-203.
14. Innohep® package insert. DuPont Pharma, Wilmington, DE, USA. July 2004.
15. Kakkar VV, Howes J, Sharma V, Kadziola Z. A comparative double-blind, randomized trial of a new second generation LMWH (bemiparin) and UFH in the prevention of post-operative venous thromboembolism. The Bemiparin Assessment group. Thromb Haemost. 2000; 83: 523-529.
16. Larsen ML, Abildgaard U, Teien AN, Gjesdal K. Assay of plasma heparin using thrombin and the chromogenic substrate H-D-Phe-Pip-Arg-pNA (S-2238). Thromb Res. 1978; 13: 285-288.
17. Lovenox® package insert. Aventis Pharma, Bridgewater, NJ, USA. July 2004.
18. MacFarlane RG. An enzyme cascade in the blood clotting mechanism, and its function as a biochemical amplifier. Nature. 1964; 202: 498-499.
19. Montalescot G, Collet JP, Lison L, Choussat R, Ankri A, Vicaut E, Perlemuter K, Philippe F, Drobinski G, Thomas D. Effects of various anticoagulant treatments on vonWillebrand factor release in unstable angina. J Am Coll Cardiol. 2000; 36: 110-114.
20. Planes A, Vochelle N, Gonzalez De Suso MJ, Claracq JP. Prophylactic antithrombotic therapy after orthopedic surgery with bemiparin, a second-generation low molecular weight heparin. Rev Esp Anestesiol Reanim. 2001; 48: 258-263.
21. Racine E. Differentiation of the low-molecular-weight heparins. Pharmacotherapy. 2001; 21: 62-70.
22. Ray KK, Morrow DA, Gibson CM, Murphy S, Antman EM, Braunwald E. Predictors of the rise in vWF after ST elevation myocardial infarction: implications for treatment strategies and clinical outcome: An ENTIRE-TIMI 23 substudy. Eur Heart J. 2005; 26: 440-446.
23. Samama MM, Gerotziafas GT. Comparative pharmacokinetics of LMWHs. Semin Thromb Hemost. 2000; 26(Suppl): 31-38.
24. Weitz JI. Low-molecular-weight heparins. N Engl J Med. 1997; 337: 688-698.